Evaluation of Maralixibat in Pruritus Associated with General Cholestatic Liver Disease (EXPAND)

Mirum Pharmaceuticals

Status and phase: Enrolling; Phase 3

Conditions: Cholestatic Liver Disease (except ALGS, PFIC, PBC and PSC)

Treatments: Drug: Maralixibat; Other: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT06553768

MRX-802

2024-511287-85-00 (EU Trial (CTIS) Number)

Details and patient eligibility

About

The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to other therapies, and who have no other treatment options.

Full description

This study will be conducted in multiple sites in North America, Europe, Middle East and South America.

Enrollment: 90 estimated patients

Sex: All

Ages: 6+ months old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Informed consent and assent (as applicable)
2. Age ≥6 months at time of baseline visit
3. Diagnosis of cholestatic liver disease with cholestatic pruritus based on the presence of chronic liver biochemical abnormalities (>90 days) and/or pathological evidence of progressive liver disease.
4. If taking antipruritics or ursodeoxycholic acid, the participant has to be on a stable dosing regimen (i.e., same dose and frequency in the 30 days prior to the screening visit and will continue this dosing regimen up to Week 40 [adjustment for body weight is allowed]).
5. Access to email or telephone for scheduled participant contacts and access to smart phone or tablet for PROs.
6. Ability to read and/or understand the questionnaires (both caregivers and participants ≥9 years of age).
7. For participants ≤18 years of age: Access to consistent caregiver(s) during the study.

Exclusion criteria

Those who meet any of the following criteria are NOT eligible to participate in the study:

1. Diagnosis of ALGS, ICP, PBC, PFIC, or PSC with native liver.

2. Current or recent history (<1 year) of atopic dermatitis or other non-cholestatic diseases associated with pruritus.

3. History of decompensated cirrhosis or complications of cirrhosis (e.g., esophageal/gastric varices, ascites, hepatic encephalopathy, hepatorenal syndrome). In patients who have had a liver transplant, this exclusion criterion applies to the post-transplant period only. Patients with compensated cirrhosis with preserved hepatic synthetic function and absence of complications are eligible.

4. Suspected or proven cholangiocarcinoma or hepatocellular carcinoma.

5. Unstable and/or serious medical disease that is likely to impair the ability to participate in all aspects of the study, confound efficacy and/or safety assessments, or result in substantially shortened life expectancy (e.g., any active malignancy including hematological malignancy, end-stage heart failure, active infection, acute and chronic diarrhea). Exceptionally, previous history of malignancy, adequately treated/in remission, that in opinion of investigator and medical monitor does not impact participant safety and participation in the study, may be allowed.

6. Laboratory results during the screening visit as follows:

   1. Platelet count ≤150,000/mm3
   2. Albumin <30 g/L
   3. INR ≥1.5 (after intravenous or subcutaneous supplementation of vitamin K)
   4. Total bilirubin >10 mg/dL
   5. ALT >10× ULN

7. Use of an IBAT inhibitor within 8 weeks prior to the screening visit.

8. Known intolerance/hypersensitivity to maralixibat or its excipients.

9. History of nonadherence to medical regimens, unreliability, medical condition, mental instability, or cognitive impairment that, in the opinion of the investigator, could compromise the validity of informed consent, compromise the safety of the participant, or lead to nonadherence with the study protocol or inability to conduct the study procedures.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

90 participants in 2 patient groups, including a placebo group

Maralixibat

Experimental group

Description:

Participants will receive maralixibat oral solution 300 μg/kg orally once daily for 1 week and then twice daily for 39 weeks.

Treatment:

Drug: Maralixibat

Placebo

Placebo Comparator group

Description:

Participants will receive placebo matched to maralixibat oral solution orally once daily for 1 week and then twice daily for 19 weeks. After 20 weeks, participants will receive maralixibat oral solution 300 μg/kg orally once daily for 1 week and then twice daily for 19 weeks.

Treatment:

Other: Placebo